ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Oculis Holding AG

Oculis Holding AG (OCS)

16,93
-0,07
(-0,41%)
Fermé 03 Janvier 10:00PM
16,93
0,00
(0,00%)
Après les heures de négociation: 11:02PM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
16,93
Prix Achat
16,75
Prix Vente
18,25
Volume échangé
9 371
16,90 Fourchette du Jour 17,30
10,10 Plage de 52 semaines 18,00
Clôture Veille
17,00
Ouverture
16,92
Dernière Transaction
7
@
16.97
Dernière heure de transaction
Volume moyen (3 m)
48 452
Volume financier
US$ 159 279
VWAP
16,9971

OCS Dernières nouvelles

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team...

Oculis to Participate at Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...

Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...

Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing

ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...

Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial

Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.If approved, OCS-01 has the potential to become the first once-daily, topical...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.47-2.7011494252917.417.416.92266317.01649465CS
41.187.4920634920615.7517.9215.45143264816.89350332CS
121.8312.11920529815.118144845216.14028504CS
265.0442.388561816711.891810.793527914.70813792CS
525.6349.823008849611.31810.13609613.38644916CS
1565.9854.611872146110.95186.262952212.56176021CS
2605.9854.611872146110.95186.262952212.56176021CS

OCS - Frequently Asked Questions (FAQ)

What is the current Oculis share price?
The current share price of Oculis is US$ 16,93
What is the 1 year trading range for Oculis share price?
Oculis has traded in the range of US$ 10,10 to US$ 18,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ONCBeiGene Ltd
 184,21
(731,65%)
132,21k
RAINRain Enhancement Technologies Holdco Inc
 6,75
(457,85%)
211,35k
NITON2OFF Inc
US$ 1,07
(331,45%)
603,87M
CTCXCarmell Corporation
US$ 0,6991
(150,48%)
314,15M
TXMDTherapeuticsMD Inc
US$ 1,58
(83,72%)
7,41M
NMRANeumora Therapeutics Inc
US$ 1,965
(-81,46%)
44,29M
THCHTH International Limited
US$ 0,71
(-80,00%)
46,39k
MARXMars Acquisition Corporation
US$ 2,47
(-73,58%)
1,19M
SISIShineco Inc
US$ 2,07
(-54,30%)
1,73M
MARXUMars Acquisition Corporation
US$ 6,23
(-40,10%)
66,1k
NITON2OFF Inc
US$ 1,07
(331,45%)
603,55M
MBIOMustang Bio Inc
US$ 0,2093
(18,25%)
310,88M
CTCXCarmell Corporation
US$ 0,6991
(150,48%)
309,04M
CGBSCrown LNG Holdings Ltd
US$ 0,6749
(68,68%)
278,33M
SVMHSRIVARU Holding Ltd
US$ 0,0599
(42,28%)
275,21M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées